Skip to main content

Table 2 Treatment and prognosis of the patients with adult-onset Still’s disease (AOSD) during follow-up

From: Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease

 

AOSD patients(N = 132)

 

AOSD patients(N = 132)

Medication

 

Prognosis

 

NSAIDs

109 (83%)

Relapse

35 (27%)

Corticosteroid

126 (95%)

MAS

17 (13%)

DMARD

88 (67%)

ICU

11 (8%)

HCQ

41 (31%)

Death

4 (3%)

Azathioprine

18 (14%)

Treatment step

 

Sulfasalazine

11 (8%)

1

1 (1%)

Leflunomide

7 (5%)

2

27 (20%)

Methotrexate

69 (52%)

3

70 (53%)

IVIG

25 (19%)

4

34 (26%)

TNF inhibitor

8 (6%)

  

IL-6 blockade

4 (3%)

  
  1. AOSD adult-onset Still’s disease, NSAIDs nonsteroidal anti-inflammatory drugs, DMARD disease modifying antirheumatic drugs, HCQ hydroxychloroquine, IVIG intravenous immunoglobulin, TNF tumor necrosis factor, IL-6 interleukin-6, MAS macrophage activation syndrome, ICU intensive unit care. Values are expressed as n (%)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096